

PCT

WORLD INTELLECTUAL PROPERTY ORGANIZATION
International Bureau



INTERNATIONAL APPLICATION PUBLISHED UNDER THE PATENT COOPERATION TREATY (PCT)

(51) International Patent Classification 7 : A61K 48/00	A1	(11) International Publication Number: WO 00/57922 (43) International Publication Date: 5 October 2000 (05.10.00)
(21) International Application Number: PCT/US00/08353 (22) International Filing Date: 30 March 2000 (30.03.00) (30) Priority Data: 60/126,800 30 March 1999 (30.03.99) US 60/138,379 9 June 1999 (09.06.99) US (71)(72) Applicants and Inventors: KORNOWSKI, Ran [US/US]; 12218 Tildenwood Drive, Rockville, MD 20852 (US). FUCHS, Shmuel [US/US]; 267 Rollins Avenue, Rockville, MD 20852 (US). EPSTEIN, Stephen, E. [US/US]; 11700 Danville Drive, Rockville, MD 20852 (US). LEON, Martin, B. [US/US]; 8822 Burdette Road, Bethesda, MD 20817 (US). (74) Agents: DIPPERT, William, H. et al.; Cowan, Liebowitz & Latman, P.C., 1133 Avenue of the Americas, New York, NY 10036-6799 (US).		(81) Designated States: AL, AM, AT, AU, AZ, BA, BB, BG, BR, BY, CA, CH, CN, CU, CZ, DE, DK, EE, ES, FI, GB, GE, GH, GM, HR, HU, ID, IL, IS, JP, KE, KG, KP, KR, KZ, LC, LK, LR, LS, LT, LU, LV, MD, MG, MK, MN, MW, MX, NO, NZ, PL, PT, RO, RU, SD, SE, SG, SI, SK, SL, TJ, TM, TR, TT, UA, UG, US, UZ, VN, YU, ZW, ARIPO patent (GH, GM, KE, LS, MW, SD, SL, SZ, TZ, UG, ZW), Eurasian patent (AM, AZ, BY, KG, KZ, MD, RU, TJ, TM), European patent (AT, BE, CH, CY, DE, DK, ES, FI, FR, GB, GR, IE, IT, LU, MC, NL, PT, SE), OAPI patent (BF, BJ, CF, CG, CI, CM, GA, GN, GW, ML, MR, NE, SN, TD, TG). Published <i>With international search report.</i>
(54) Title: INTRAMYOCARDIAL INJECTION OF AUTOLOGOUS BONE MARROW (57) Abstract A method of treating cardiac or myocardial conditions comprises the administration of an effective amount of autologous bone marrow. The bone marrow may optionally be stimulated and/or administered in combination with a pharmaceutical drug, protein, gene or other factor or therapy that may enhance bone marrow production of angiogenic growth factors and/or promote endothelial cell proliferation or migration or blood vessel formation.		

Applicant: Silviu Itescu
U.S. Serial No.: 10/693,480
Filed: October 23, 2003
Exhibit 1

FOR THE PURPOSES OF INFORMATION ONLY

Codes used to identify States party to the PCT on the front pages of pamphlets publishing international applications under the PCT.

AL	Albania	ES	Spain	LS	Lesotho	SI	Slovenia
AM	Armenia	FI	Finland	LT	Lithuania	SK	Slovakia
AT	Austria	FR	France	LU	Luxembourg	SN	Senegal
AU	Australia	GA	Gabon	LV	Latvia	SZ	Swaziland
AZ	Azerbaijan	GB	United Kingdom	MC	Monaco	TD	Chad
BA	Bosnia and Herzegovina	GE	Georgia	MD	Republic of Moldova	TG	Togo
BB	Barbados	GH	Ghana	MG	Madagascar	TJ	Tajikistan
BE	Belgium	GN	Guinea	MK	The former Yugoslav Republic of Macedonia	TM	Turkmenistan
BF	Burkina Faso	GR	Greece	ML	Mali	TR	Turkey
BG	Bulgaria	HU	Hungary	MN	Mongolia	TT	Trinidad and Tobago
BJ	Benin	IE	Ireland	MR	Mauritania	UA	Ukraine
BR	Brazil	IL	Israel	MW	Malawi	UG	Uganda
BY	Belarus	IS	Iceland	MX	Mexico	US	United States of America
CA	Canada	IT	Italy	NE	Niger	UZ	Uzbekistan
CF	Central African Republic	JP	Japan	NL	Netherlands	VN	Viet Nam
CG	Congo	KE	Kenya	NO	Norway	YU	Yugoslavia
CH	Switzerland	KG	Kyrgyzstan	NZ	New Zealand	ZW	Zimbabwe
CI	Côte d'Ivoire	KP	Democratic People's Republic of Korea	PL	Poland		
CM	Cameroon	KR	Republic of Korea	PT	Portugal		
CN	China	KZ	Kazakhstan	RO	Romania		
CU	Cuba	LC	Saint Lucia	RU	Russian Federation		
CZ	Czech Republic	LJ	Liechtenstein	SD	Sudan		
DE	Germany	LK	Sri Lanka	SE	Sweden		
DK	Denmark	LR	Liberia	SG	Singapore		
EE	Estonia						

INTRAMYOCARDIAL INJECTION OF AUTOLOGOUS BONE MARROW

5

FIELD OF THE INVENTION

This application is directed to a method of injecting autologous bone marrow. More specifically, this invention is directed to intramyocardial injection of autologous bone marrow to enhance collateral blood vessel formation and tissue perfusion.

10

BACKGROUND OF THE INVENTION

The use of recombinant genes or growth-factors to enhance myocardial collateral blood vessel function may represent a new approach to the treatment of cardiovascular disease. Kornowski, R., et al., "Delivery strategies for therapeutic myocardial angiogenesis", *Circulation* 2000; 101:454-458. Proof of concept has been demonstrated in animal models of myocardial ischemia, and clinical trials are underway. Unger, E.F., et al., "Basic fibroblast growth factor enhances myocardial collateral flow in a canine model", *Am J Physiol* 1994; 266:H1588-1595; Banai, S. et al., "Angiogenic-induced enhancement of collateral blood flow to ischemic myocardium by vascular endothelial growth factor in dogs", *Circulation* 1994; 83:2189; Lazarous, D.F., et al., "Effect of chronic systemic administration of basic fibroblast growth factor on collateral development in the canine heart", *Circulation* 1995; 91:145-153; Lazarous, D.F., et al., "Comparative effects of basic development and the arterial response to injury", *Circulation* 1996; 94:1074-1082; Giordano, F.J., et al., "Intracoronary gene transfer of fibroblast growth factor-5 increases blood flow and contractile function in an ischemic region of the heart", *Nature Med* 1996; 2:534-9. Most strategies for trans-catheter delivery of angiogenic factors have employed an intracoronary route which may have limitations due to imprecise localization of genes or proteins and systemic delivery to non-cardiac tissue. Thus, it would be desirable to have the

capacity for direct delivery of angiogenic factors or genes to precisely defined regions of the myocardium rather than to the entire heart, and to minimize the potential for systemic exposure. Guzman, R.J., et al., "Efficient gene transfer into myocardium by direct injection of adenovirus vectors", *Circ Res* 1993; 73:1202-7; Mack, C.A., et al., "Biologic bypass
5 with the use of adenovirus-mediated gene transfer of the complementary deoxyribonucleic acid for VEGF-121, improves myocardial perfusion and function in the ischemic porcine heart", *J Thorac Cardiovasc Surg* 1998;115:168-77.

The effect of direct intra-operative intramyocardial injection of angiogenic factors on collateral function has been studied in animal models of myocardial ischemia. Open
10 chest, transepical administration of an adenoviral vector containing a transgene encoding an angiogenic peptide resulted in enhanced collateral function. (Mack et al., *supra*.) Angiogenesis was also reported to occur with direct intramyocardial injection of an angiogenic peptide or a plasmid vector during open heart surgery in patients. Schumacher, B., et al., "Induction of neoangiogenesis in ischemic myocardium by human growth factors.
15 First clinical results of a new treatment of coronary heart disease", *Circulation* 1998; 97:645-650; Losordo, D.W., et al., "Gene therapy for myocardial angiogenesis: initial clinical results with direct myocardial injection of phVEGF165 as sole therapy for myocardial ischemia", *Circulation* 1998; 98:2800.

Despite the promising hope for therapeutic angiogenesis as a new modality to treat
20 patients with coronary artery disease, there is still a huge gap regarding what specific strategy will optimally promote a clinically relevant therapeutic angiogenic response. Moreover, it is unclear which one (or more) out of multiple angiogenic growth factors may be associated with a beneficial angiogenic response. In addition, the use of different tissue delivery platforms, e.g., proteins, adenovirus, or "naked" DNA, to promote the optimal
25 angiogenic response has remained an open issue.

OBJECTS OF THE INVENTION

It is an object of this invention to provide a novel therapeutic modality wherein autologous bone marrow is injected to promote angiogenesis in the injected tissue.

It is also an object of this invention to provide a novel method of intramyocardial
5 injection to enhance collateral blood vessel formation and tissue perfusion.

These and other objects of the invention will become more apparent in the discussion below.

SUMMARY OF THE INVENTION

10 Most currently tested therapeutic approaches have focused on a single angiogenic growth factor (e.g., VEGF, FGF, angiopoietin-1) delivered to the ischemic tissue. This can be accomplished either by delivery of the end-product (e.g., protein) or by gene transfer, using diverse vectors. However, it is believed that complex interactions among several growth factor systems are probably necessary for the initiation and maintenance of new
15 blood vessel formation. More specifically, it is believed important to induce a specific localized angiogenic milieu with various angiogenic cytokines interacting in concert and in a time-appropriate manner to initiate and maintain the formation and function of new blood vessels.

The bone marrow (BM) is a natural source of a broad spectrum of cytokines and
20 cells that are involved in the control of angiogenic processes. It is therefore believed that the intramyocardial injection of autologous (A) BM, by taking advantage of the natural ability of these cells to secrete many angiogenic factors in a time-appropriate manner, provides an optimal intervention for achieving therapeutic collateral development in ischemic myocardium.

According to the invention autologous bone marrow is injected, either as a "stand alone" therapeutic agent or combined with any pharmacologic drug, protein or gene or any other compound or intervention that may enhance bone marrow production of angiogenic growth factors and/or promote endothelial cell proliferation, migration, and blood vessel tube formation. The "combined" agent(s) can be administered directly into the patient or target tissue, or incubated ex-vivo with bone marrow prior to injection of bone marrow into the patient. Non-limiting examples of these "combined" agents are Granulocyte-Monocyte Colony Stimulatory Factor (GM-CSF), Monocyte Chemoattractant Protein 1 (MCP-1), and Hypoxia Inducible Factor-1 (HIF-1). An example of an intervention that may enhance bone marrow production of angiogenic factors is ex-vivo exposure of bone marrow cells to hypoxia. The autologous bone marrow, alone or with "combined" agents, can be delivered to the patient directly via either trans-endocardial or trans-epicardial approaches into either ischemic and/or non-ischemic myocardium, or directly into any other ischemic organ (including a peripheral limb) to enhance and/or promote the development of collateral blood vessel formation and therefore collateral flow to ischemic myocardium or ischemic limbs. This approach can also be used to promote the development of newly implanted dedifferentiated and/or differentiated myocardial cells by the process of cardiac myogenesis.

The invention comprises various autologous bone marrow transplantation strategies to enhance angiogenesis and/or myogenesis and thereby accelerate the development of new blood vessels into ischemic myocardium or lower extremities. Another aspect of the invention concerns the strategy of "optimization of angiogenic gene expression." This strategy employs co-administration of HIF-1 with the autologous bone marrow. HIF-1 is a transcription factor known to be induced and activated by hypoxia, and known to induce expression of multiple genes involved in the response to hypoxia. A similar approach involves the exposure of autologous bone marrow to endothelial PAS domain protein 1

(EPAS1). EPAS1 shares high structural and functional homology with HIF-1. The strategy also involves the ex-vivo exposure of the bone marrow to hypoxia to increase the production of vascular endothelial growth factor (VEGF) expression or other cytokines with proven angiogenic activity (such as MCP-1) prior to its direct injection into the heart or
5 any peripheral ischemic tissue. This invention thus includes the direct intramyocardial (trans-epicardial or trans-endocardial) or peripheral intramuscular injection of autologous bone marrow; stimulated autologous bone marrow, for example, stimulated by HIF-1, EPAS1, MCP-1, GM-CSF, or transient exposure to hypoxia or other forms of energy, such as ultrasound, RF, electromagnetic or laser energy; or autologous bone marrow product
10 derived from conditioned medium (acellular component/s of cultured bone marrow). The stimulation of the bone marrow could be by the direct exposure of the bone marrow to the factors in the form of proteins, or the bone marrow cells can be transfected with vectors carrying the relevant genes. For example, bone marrow can be transfected with a plasmid vector, or with an adenoviral vector, carrying the HIF-1 or EPAS1 transgenes.

15

BRIEF DESCRIPTION OF THE DRAWINGS

Fig. 1 is a graph of the proliferation of PAEC's vs. the quantities of conditioned medium;

Fig. 2 is a graph of the proliferation of endothelial cells vs. the quantities of
20 conditioned medium;

Fig. 3 is a graph of the concentration of VEGF in conditioned medium over a four-week period of time; and

Fig. 4 is a graph of the concentration of MCP-1 in conditioned medium over a four-week period of time.

DETAILED DESCRIPTION OF THE INVENTION

Bone marrow is a natural source of a broad spectrum of cytokines that are involved in the control of angiogenic and inflammatory processes. The cytokines expressed comprise mediators known to be involved in the maintenance of early and late hematopoiesis (IL-1 alpha and IL-1beta, IL-6, IL-7, IL-8, IL-11 and IL-13; colony-stimulating factors, thrombopoietin, erythropoietin, stem cell factor, flt 3-ligand, hepatocyte cell growth factor, tumor necrosis factor alpha, leukemia inhibitory factor, transforming growth factors beta 1 and beta 3; and macrophage inflammatory protein 1 alpha), angiogenic factors (fibroblast growth factors 1 and 2, vascular endothelial growth factor) and mediators whose usual target (and source) is the connective tissue-forming cells (platelet-derived growth factor A, epidermal growth factor, transforming growth factors alpha and beta 2, oncostatin M and insulin-like growth factor-1), or neuronal cells (nerve growth factor). Sensebe, L., et al., *Stem Cells* 1997; 15:133-43. Moreover, it has been shown that VEGF polypeptides are present in platelets and megacaryocytes, and are released from activated platelets together with the release of beta-thromboglobulin. Wartiovaara, U., et al., *Thromb Haemost* 1998; 80:171-5; Mohle, R., *Proc Natl Acad Sci U S A* 1997; 94:663-8.

There are also indicators to support the concept that angiogenesis is needed to support bone marrow function and development of hematopoietic cells, including stem cells and progenitor cells, that may enter the circulation and target to sites of wound healing and/or ischemia, ultimately contributing to new blood vessel formation. Monoclonal antibodies that specifically recognize undifferentiated mesenchymal progenitor cells isolated from adult human bone marrow have been shown to recognize cell surface markers of developing microvasculature, and evidence suggests such cells may play a role in embryonal angiogenesis. Fleming, J.E., Jr., *Dev Dyn* 1998; 212:119-32.

Bone marrow angiogenesis may become exaggerated in pathologic states where the bone marrow is being activated by malignant cells (such as in multiple myeloma) where

bone marrow angiogenesis has been shown to increase simultaneously with progression of human multiple myeloma cells. Ribatti, D., et al., *Br J Cancer* 1999; 79:451-5. Moreover, vascular endothelial growth factor (VEGF) has been shown to play a role in the growth of hematopoietic neoplasms such as multiple myeloma, through either a paracrine or an
5 autocrine mechanism. Bellamy, W.T., *Cancer Res* 1999; 59:728-33; Fiedler, W., *Blood* 1997; 89:1870-5). It is believed that autologous bone marrow, with its unique native humoral and cellular properties, is a potential source of various angiogenic compounds. This natural source of "mixed" angiogenic cytokines can surprisingly be utilized as a mixture of potent interactive growth factors to produce therapeutic angiogenesis and/or
10 myogenesis; use of the cells per se could provide a more sustained source of these natural angiogenic agents.

One of the factors that most likely participates in initiating angiogenesis in response to ischemia is HIF-1, a potent transcription factor that binds to and stimulates the promoter of several genes involved in responses to hypoxia. Induction and activation of HIF-1 is
15 tightly controlled by tissue pO₂; HIF-1 expression increases exponentially as pO₂ decreases, thereby providing a positive feedback loop by which a decrease in pO₂ causes an increase in the expression of gene products that serve as an adaptive response to a low oxygen environment. Activation of HIF-1 leads, for example, to the induction of erythropoietin, genes involved in glycolysis, and to the expression of VEGF. It probably
20 also modulates the expression of many other genes that participate in the adaptive response to low pO₂ levels. The mechanism by which HIF-1 regulates levels of proteins involved in the response to hypoxia is through transcriptional regulation of genes responding to low pO₂. Thus, such genes have short DNA sequences within the promoter or enhancer regions that contain HIF-1 binding sites, designated as hypoxia responsive elements (HRE). HIF-1
25 is a heterodimer with a basic helix-loop-helix motif, consisting of the subunits HIF-1 α and HIF-1 β . Its levels are regulated by pO₂ both transcriptionally and posttranscriptionally—

HIF-1 induction is increased by hypoxia, and its half-life is markedly reduced as pO₂ levels increase.

It is relevant that while expression of HIF-1 (as determined in HeLa cells) is exponentially and inversely related to pO₂, the inflection point of the curve occurs at an oxygen saturation of 5%, with maximal activity at 0.5% and ½ maximal activity at 1.5-2.0% . These are relatively low levels of hypoxia, and it is not clear whether such levels occur in the presence of mild levels of myocardial or lower limb ischemia—i.e., levels present in the absence of tissue necrosis (myocardial infarction, and leg ulcerations, respectively). Thus, bone marrow cells could have the capacity to secrete angiogenic factors and thereby enhance collateral development. However, it is possible that such activity may not become manifest in the specific tissue environments treated unless some additional stimulus is present. It is, therefore, a preferred aspect of the invention to co-administer, if necessary, bone marrow implant with HIF-1. It is anticipated that HIF-1 will provide optimal expression of many of the hypoxia-inducible angiogenic genes present in the bone marrow implant. The HIF-1 can be injected either as the protein, or as the gene. If as the latter, it can be injected either in a plasmid or viral vector, or any other manner that leads to functionally relevant protein levels. For example, bone marrow can be transfected, *ex vivo*, with a plasmid vector, or with an adenoviral vector, carrying the HIF-1 or EPAS1 transgenes. It is emphasized, however, that HIF-1 is used in this section as an example of an intervention that could enhance production of angiogenic substances by bone marrow. This invention also covers use of other agents, which by enhancing HIF-1 activity (i.e., prolonging its half-life), or by producing effects analogous to HIF-1, stimulate the bone marrow to increase expression of angiogenic factors. A similar approach involves the exposure of autologous bone marrow to endothelial PAS domain protein 1 (EPAS1). EPAS1 shares high structural and functional homology with HIF-1.

Because VEGF promoter activity is enhanced by HIF-1, this invention also includes the ex-vivo exposure of bone marrow cells in culture to hypoxia or other forms of energy, such as, for example, ultrasound, RF, or electromagnetic energy. This intervention increases VEGF and other gene expression. By this effect it may augment the capacity of
5 bone marrow to stimulate angiogenesis.

Another aspect of the invention involves the *ex-vivo* stimulation of aspirated autologous bone marrow by HIF-1 (or products that augment the effects of HIF-1 or produce similar effects to HIF-1 on bone marrow) or direct exposure of bone marrow to hypoxic environment followed by the delivery of activated bone marrow cells to the
10 ischemic myocardium or peripheral organ (e.g., ischemic limb) to enhance collateral-dependent perfusion in cardiac and/or peripheral ischemic tissue. The stimulation of the bone marrow could be by the direct exposure of the bone marrow to the factors in the form of proteins, or the bone marrow cells can be transfected with vectors carrying the relevant genes. For example, bone marrow can be transfected with a plasmid vector, or with an
15 adenoviral vector, carrying the HIF-1 or EPAS1 transgenes.

Current data indicate the importance of monocyte-derived cytokines for enhancing collateral function. Monocytes are activated during collateral growth in vivo, and monocyte chemotactic protein-1 (MCP-1) is upregulated by shear stress in vitro. It has been shown that monocytes adhere to the vascular wall during collateral vessel growth (arteriogenesis)
20 and capillary sprouting (angiogenesis). MCP-1 was also shown to enhance collateral growth after femoral artery occlusion in the rabbit chronic hindlimb ischemia model (Ito et al., *Circ Res* 1997; 80:829-3). Activation of monocytes seems to play an important role in collateral growth as well as in capillary sprouting. Increased monocyte recruitment by LPS is associated with increased capillary density as well as enhanced collateral and peripheral
25 conductance at 7 days after experimental arterial occlusion (Arras M. et al., *J Clin Invest* 1998;101:40-50.).

A further aspect of the invention involves the *ex-vivo* stimulation of aspirated autologous bone marrow by MCP-1, followed by the direct delivery of activated bone marrow cells to the ischemic myocardium or peripheral organ (e.g., ischemic limb) to enhance collateral-dependent perfusion and muscular function in cardiac and/or peripheral
5 ischemic tissue. The stimulation of the bone marrow could be by the direct exposure of the bone marrow to MCP-1 in the form of the protein, or the bone marrow cells can be transfected with a vector carrying the MCP-1 gene. For example, bone marrow can be transfected with a plasmid vector, or with an adenoviral vector, carrying the MCP-1 transgene.

10 Granulocyte-macrophage colony-stimulating factor (GM-CSF) and Granulocyte-Colony Stimulatory Factor (G-CSF) are stimulatory cytokines for monocyte maturation and are multipotent hematopoietic growth factors, which are utilized in clinical practice for various hematological pathologies such as depressed white blood cell count (i.e., leukopenia or granulocytopenia or monocytopenia) which occurs usually in response to
15 immunosuppressive or chemotherapy treatment in cancer patients. GM-CSF has also been described as a multilineage growth factor that induces *in vitro* colony formation from erythroid burst-forming units, eosinophil colony-forming units (CSF), and multipotential (CSF), as well as from granulocyte-macrophage CSF and granulocyte CFU. (Bot F.J., *Exp Hematol* 1989, 17:292-5). *Ex-vivo* exposure to GM-CSF has been shown to induce rapid
20 proliferation of CD-34+ progenitor cells (Egeland T. et al., *Blood* 1991; 78:3192-9.) These cells have the potential to differentiate into vascular endothelial cells and may naturally be involved in postnatal angiogenesis. In addition, GM-CSF carries multiple stimulatory effects on macrophage/monocyte proliferation, differentiation, motility and survival (reduced apoptotic rate). Consistent with the combined known effects on bone marrow
25 derived endothelial progenitor cells and monocytes, it is another aspect of the invention to use GM-CSF as an adjunctive treatment to autologous bone marrow injections aimed to

induce new blood vessel formation and differentiation in ischemic cardiovascular organs. Moreover, GM-CSF may further enhance therapeutic myocardial angiogenesis caused by bone marrow, by augmenting the effect of bone marrow, or by further stimulating, administered either in vivo or in vitro, bone marrow that is also being stimulated by agents
5 such as HIF-1, EPAS1, hypoxia, or MCP-1.

In the examples below, certain testing regarding aspects of the invention is set forth. These examples are non-limitative.

EXAMPLES

10 EXAMPLE 1

Effect of Bone Marrow Cultured Media on Endothelial Cell Proliferation

Studies were conducted to determine whether aspirated pig autologous bone marrow cells obtained secreted VEGF, a potent angiogenic factor, and MCP-1, which recently has been identified as an important angiogenic co-factor. Bone marrow was cultured in vitro for
15 four weeks. The conditioned medium was added to cultured pig aortic endothelial cells (PAECs), and after four days proliferation was assessed. VEGF and MCP-1 levels in the conditioned medium were assayed using ELISA. During the four weeks in culture, BM cells secreted VEGF and MCP-1, such that their concentrations increased in a time-related manner. The resulting conditioned medium enhanced, in a dose-related manner, the
20 proliferation of PAECs. The results indicate that BM cells are capable of secreting potent angiogenic cytokines such as VEGF and MCP-1 and of inducing proliferation of vascular endothelial cells.

Pig Bone Marrow Culture

Bone marrow (BM) cells were harvested under sterile conditions from pigs with chronic myocardial ischemia in preservative free heparin (20 units/ml BM cells) and filtered sequentially using 300 μ and 200 μ stainless steel mesh filters. BM cells were then
5 isolated by Ficoll-Hypaque gradient centrifugation and cultured in long-term culture medium (LTCM) (Stem Cell Tech, Vancouver, British Columbia, Canada) at 33 $^{\circ}$ C with 5% CO $_2$ in T-25 culture flask. The seeding density of the BMCs in each culture was 7 x 10 6 /ml. Weekly, one half of the medium was removed and replaced with fresh LTCM. The removed medium was filtered (0.2 μ filter) and stored at -200 $^{\circ}$ C for subsequent
10 Enzyme-linked Immunosorbent Assay (ELISA) and cell proliferation assays.

Isolation and Culture of Pig Aortic Endothelial Cells

Fresh pig aortic endothelial cells (PAECs) were isolated using conventional methods. Endothelial cell growth medium (EGM-2 medium, Clonetics, San Diego, CA), containing 2% FBS, hydrocortisone, human FGF, VEGF, human EGF, IGF, heparin and
15 antibiotics, at 37 $^{\circ}$ C with 5% carbon dioxide. When the cells became confluent at about 7 days, they were split by 2.5% trypsin and cultured thereafter in medium 199 with 10% FBS. Their identity was confirmed by typical endothelial cell morphology and by immunohistochemistry staining for factor VIII. Passage 3-10 were used for the proliferation study.

20 Effects of conditioned medium on aortic endothelial cells

Cell proliferation assay: PAECs (Passage 3-10) were removed from culture flasks by trypsinization. The detached cells were transferred to 96-well culture plates and plated at a seeding density of 5,000 cells /well. Cells were cultured for 2 – 3 days before being used in proliferation and DNA synthesis experiments. The conditioned medium of BM cells
25 cultures were collected at 4 weeks; medium from 7 culture flasks were pooled and used in

the bioassay. Aliquotes (10 μ L, 30 μ L, 100 μ L or 200 μ L) of pooled conditioned medium, or LTCM (200 μ L, as control), were added to confluent PAECs in 96-well plates in triplicate. Four days following culture with conditioned medium or control medium, the PAECs were trypsinized and counted using a cell counter (Coulter Counter Beckman Corporation, Miami FL).

Effects of Conditioned Medium on PAEC DNA Synthesis

Aliquotes (10 μ L, 30 μ L, 100 μ L or 200 μ L) of conditioned medium from pooled samples or control medium (LTCM, 200 μ L) were added to PAECs in 96-well plate (same seeding density as above) in triplicate. After 2 days, 1 μ Ci tritiated thymidine was added to each well. Forty-eight hours later, DNA in PAECs was harvested using a cell harvester (Mach III M Tomtec, Hamden, CT) and radioactivity was counted by liquid scintillation counter (Multi-detector Liquid Scintillation Luminescence Counter EG&G Wallac, Turku, Finland).

Determination of VEGF and MCP-1 in conditioned medium by ELISA VEGF

The concentration of VEGF in conditioned medium was measured using a sandwich ELISA kit (Chemicon International Inc., Temecula, CA). Briefly, a plate pre-coated with anti-human VEGF antibody was used to bind VEGF in the conditioned medium or to a known concentration of recombinant VEGF. The complex was detected by the biotinylated anti-VEGF antibody, which binds to the captured VEGF. The biotinylated VEGF antibody in turn was detected by streptavidin-alkaline phosphatase and color generating solution. The anti-human VEGF antibody cross-reacts with porcine VEGF.

Determination of MCP-1 in conditioned medium by ELISA

The concentration of MCP-1 in conditioned medium was assayed by sandwich enzyme immunoassay kit (R & D Systems, Minneapolis, MN): a plate pre-coated with anti

human MCP-1 antibody was used to bind MCP-1 in the conditioned medium or to a known concentration of recombinant protein. The complex was detected by the biotinylated anti-MCP-1 antibody, which binds to the captured MCP-1. The biotinylated MCP-1 antibody in turn was detected by streptavidin-alkaline phosphatase and color generating solution. The
5 anti-human MCP-1 antibody cross-reacts with porcine MCP-1.

Results

The BM conditioned medium collected at four weeks increased, in a dose-related manner, the proliferation of PAECs (Fig. 1). This was demonstrated by counting the
10 number of cells directly and by measuring tritiated thymidine uptake ($p < 0.001$ for both measurements). The dose-related response demonstrated a descending limb; proliferation decreased with 200 μL conditioned medium compared to 30 μL and 100 μL ($P = 0.003$ for both comparisons). Similar dose-related results were observed in the tritiated thymidine uptake studies ($P = 0.03$ for 30 μL and 100 μL compared to 200 μL , respectively).

15 A limited number ($5 \pm 4\%$) of freshly aspirated BM cells stained positive for factor VIII. The results are set forth in Fig. 2. This contrasted to $57 \pm 14\%$ of the adherent layer of BM cells cultured for 4 weeks, of which $60 \pm 23\%$ were endothelial-like cells and $40 \pm 28\%$ appeared to be megakaryocytes.

Over a 4-week period, the concentrations of VEGF and MCP-1 in the BM
20 conditioned medium increased gradually to 10 and 3 times the 1st week level, respectively ($P < 0.001$ for both comparisons) (Fig. 3). In comparison, VEGF and MCP-1 levels in a control culture medium, not exposed to BM, were 0 and 11 ± 2 pg/ml, respectively, as shown in Fig. 4.

EXAMPLE 2

Effects of Hypoxia on VEGF Secretion by Cultured Pig Bone Marrow Cells

It was demonstrated that hypoxia markedly increases the expression of VEGF by
5 cultured bone marrow endothelial cells, results indicating that ex-vivo exposure to hypoxia,
by increasing expression of hypoxia-inducible angiogenic factors, can further increase the
collateral enhancing effect of bone marrow cells and its conditioned media to be injected in
ischemic muscular tissue. Pig bone marrow was harvested and filtered sequentially using
300 μ and 200 μ stainless steel mesh filters. BMCs were then isolated by Ficoll-Hypaque
10 gradient centrifugation and cultured at 33° C with 5% CO₂ in T-75 culture flasks. When
cells became confluent at about 7 days, they were split 1:3 by trypsinization. After 4 wks
of culture, the BMCs were either exposed to hypoxic conditions (placed in a chamber
containing 1% oxygen) for 24 to 120 hrs, or maintained under normal conditions. The
resulting conditioned medium was collected and VEGF, MCP-1 were analyzed by ELISA.

15 Exposure to hypoxia markedly increased VEGF secretion: At 24 hrs VEGF
concentration increased from 106 ± 13 pg/ml under normoxic, to $1,600 \pm 196$ pg/ml under
hypoxic conditions ($p=0.0002$); after 120 hrs it increased from $4,163 \pm 62$ to $6,028 \pm 167$
pg/ml ($p<0.0001$). A separate study was performed on freshly isolated BMCs, and the
same trend was found. Hypoxia also slowed the rate of proliferation of BMCs. MCP-1
20 expression was not increased by hypoxia, a not unexpected finding as its promoter is not
known to have HIF binding sites.

EXAMPLE 3

Effect of Bone Marrow Cultured Media on Endothelial Cell Tube Formation

It was demonstrated, using pig endothelial cells and vascular smooth muscle cells co-culture technique, that the conditioned medium of bone marrow cells induced the formation of structural vascular tubes in vitro. No such effect on vascular tube formation was observed without exposure to bone marrow conditioned medium. The results suggest that bone marrow cells and their secreted factors exert pro-angiogenic effects.

EXAMPLE 4

The effect of Transendocardial Delivery of Autologous Bone Marrow on Collateral Perfusion and Regional Function in Chronic Myocardial Ischemia Model

Chronic myocardial ischemia was created in 14 pigs by the implantation of ameroid constrictors around the left circumflex coronary artery. Four weeks after implantation, 7 animals underwent transendocardial injections of freshly aspirated ABM into the ischemic zone using a transendocardial injection catheter (2.4 ml per animal injected at 12 sites) and 7 control animals were injected with heparinized saline. At baseline and 4 weeks later, animals underwent rest and pacing echocardiogram to assess regional contractility (% myocardial thickening), and microsphere study to assess collateral-dependent perfusion at rest and during adenosine infusion. Four weeks after injection of ABM collateral flow (expressed as the ratio of ischemic/normal zone x 100) improved in ABM-treated pigs but not in controls (ABM: 95 ± 13 vs 81 ± 11 at rest, $P=0.017$; 85 ± 19 vs 72 ± 10 during adenosine, $P=0.046$; Controls: 86 ± 14 vs 86 ± 14 at rest, $P=NS$; 73 ± 17 vs 72 ± 14 during adenosine, $P=0.63$). Similarly, contractility increased in ABM-treated pigs but not in controls (ABM: 83 ± 21 vs 60 ± 32 at rest, $P=0.04$; 91 ± 44 vs 35 ± 43 during pacing,

P=0.056, Controls: 69 ± 48 vs 64 ± 46 at rest, $P=0.74$; 65 ± 56 vs 37 ± 56 during pacing, $P=0.23$).

The results indicate that catheter-based transendocardial injection of ABM can augment collateral perfusion and myocardial function in ischemic myocardium, findings suggesting that this approach may constitute a novel therapeutic strategy for achieving optimal therapeutic angiogenesis.

Fourteen specific-pathogen-free domestic pigs weighing approximately 70 kg were anesthetized, intubated, and received supplemental O_2 at 2 L/min as well as 1-2% isoflurane inhalation throughout the procedure. Arterial access was obtained via right femoral artery isolation and insertion of an 8 French sheath. The left circumflex artery was isolated through a left lateral thoracotomy and a metal encased ameroid constrictor was implanted at the very proximal part of the artery. Four weeks after the ameroid constrictor implantation all pigs underwent (1) a selective left and right coronary angiography for verification of ameroid occlusion and assessment of collateral flow; (2) transthoracic echocardiography studies; and (3) regional myocardial blood flow assessment.

Bone Marrow Aspiration and Preparation and Intramyocardial Injection

Immediately after completion of the baseline assessment, all animals underwent BM aspiration from the left femoral shaft using standard techniques. BM was aspirated from 2 sites (3 ml per site) using preservative free heparinized glass syringes (20 unit heparin/1 ml fresh BM). The aspirated bone marrow was immediately macro-filtered using 300μ and 200μ stainless steel filters, sequentially. Then, the bone marrow was injected using a trans-endocardial injection catheter into the myocardium in 12 sites (0.2 ml per injection site for total of 2.4. ml) directed to the ischemic myocardial territory and its borderline region.

Echocardiography Study

Transthoracic echocardiography images of short and long axis views at the mid-papillary muscle level were recorded in animals at baseline and during pacing, at baseline and during follow-up evaluation at four weeks after ABM implantation. Fractional
5 shortening measurements were obtained by measuring the % wall thickening (end-systolic thickness minus end-diastolic thickness / end-diastolic thickness) x 100. Those measurements were taken from the ischemic territory (lateral area) and remote territory (anterior-septal area). Subsequently, a temporary pacemaker electrode was inserted via a right femoral venous sheath and positioned in the right atrium. Animals were paced at
10 180/minute for 2 minutes and echocardiographic images were simultaneously recorded.

Regional Myocardial Blood Flow

Regional myocardial blood flow measurements were performed at rest and during maximal coronary vasodilation by use of multiple fluorescent colored microspheres (Interactive Medical Technologies, West Los Angeles, CA) and quantified by the reference
15 sample technique (Heymann MA, et al., *Prog Cardiovasc Dis* 1977;20:55-79). Fluorescent microspheres (0.8 ml, 5x10⁶ microspheres/ml, 15 µm diameter in a saline suspension with 0.01% Tween 80) were injected into the left atrium via a 6F Judkins left 3.5 diagnostic catheter. Maximal coronary vasodilation was induced by infusing adenosine at a constant rate of 140 µg/kg/min (Fujisawa USA, Deerfield, IL) into the left femoral vein over a
20 period of 6 minutes. During the last 2 minutes of the infusion, microsphere injection and blood reference withdrawal were undertaken in identical fashion to the rest study.

Following completion of the perfusion assessment, animals were sacrificed with an overdose of sodium pentobarbital and KCL. Hearts were harvested, flushed with Ringer Lactate, perfusion-fixed for 10-15 minutes, and subsequently immersion-fixed with 10%
25 buffered formaldehyde for 3 days. After fixation was completed, the hearts were cut along

the short axis into 7-mm thick slices. The 2 central slices were each divided into 8 similar sized wedges, which were further cut into endocardial and epicardial subsegments. The average of 8 lateral ischemic zone and 8 septal normal zone sub-segments measurements were used for assessment of endocardial and epicardial regional myocardial blood flow.

- 5 The relative collateral flow was also computed as the ratio of the ischemic zone/non ischemic zone (IZ/NIZ) blood flow.

Histopathology

- To assess whether injecting BM aspirate via the use of an injection catheter was associated with mechanical cell damage, standard BM smears were prepared before and
10 after propelling the freshly filtered ABM aspirate through the needle using similar injecting pressure as in the *in-vivo* study. Morphological assessment was performed by an independent experienced technician who was blinded to the study protocol.

- Histopathology assessment was performed on sampled heart tissue. In the pilot study, 7-mm thick short-axis slices were examined under UV light to identify fluorescent-
15 tagged areas. Each identified area was cut into 3 full thickness adjacent blocks (central, right and left) that were immersion-fixed in 10% buffered formaldehyde. Subsequently, each such block was cut into 3 levels, of which 2 were stained with Hematoxylin and Eosin (H&E) and one with PAS. In addition, one fresh fluorescent-labeled tissue block was obtained from the ischemic region of each animal and was embedded in OCT compound
20 (Sakura Finetek USA Inc., Torance, CA) and frozen in liquid nitrogen. Frozen sections of these snap-frozen myocardial tissue were air dried and fixed with acetone. Immunoperoxidase stain was performed with the automated Dako immuno Stainer (Dako, Carpinteria, CA). The intrinsic peroxidase and non-specific uptake were blocked with 0.3% hydrogen peroxidase and 10% ovo-albumin. Monoclonal mouse antibody against CD-34
25 (Becton Dickinson, San Jose, CA) was used as the primary antibody. The linking antibody was a biotinylated goat anti-mouse IgG antibody and the tertiary antibody was streptavidin

conjugated with horse reddish peroxidase. Diaminobenzidine (DAB) was used as the chromogen and the sections were counterstained with 1% methylgreen. After dehydration and clearing, the slides were mounted and examined with a Nikon Labphot microscope.

In the efficacy study, full-thickness, 1.5 square centimeter sections from the ischemic and non-ischemic regions were processed for paraffin sections. Each of the samples was stained with H&E, Masson's trichrome, and factor VIII related antigen. The immunoperoxidase stained slides were studied for density of endothelial cell population and vascularization. The latter was distinguished from the former by the presence of a lumen. Vascularity was assessed using 5 photomicrographs samples of the factor VIII stained slides taken from the inner half of the ischemic and non-ischemic myocardium. Density of endothelial cells was assessed using digitized images of the same photomicrographs. The density of the endothelial population was determined by Sigma-Scan Pro morphometry software using the intensity threshold method. The total endothelial area for each sample as well as for each specimen were obtained along with the relative percent endothelial area (endothelial area / area of the myocardium studied). The total endothelial area was also calculated as the relative percent of the non-infarcted (viable) area of the myocardium studied. The trichrom stained sections were digitized and the area occupied by the blue staining collagen as well as the total area of the section excluding the area occupied by the epicardium (which normally contained collagen) were measured using Sigma-Scan Pro. The infarcted area was then calculated as the area occupied by the blue staining.

Procedural Data

Intra-myocardial injections either with ABM or placebo were not associated with any acute change in mean blood pressure, heart rate or induction of arrhythmia. All hemodynamic parameters were comparable between the two groups. Pair-wise comparison showed similar hemodynamic parameters within each group in the index compared to the follow-up procedure except for higher initial mean arterial blood pressure at follow-up in

the control group ($P=0.03$) with no subsequent differences during pacing or adenosine infusion.

Myocardial Function

Regional myocardial function assessment is shown in Table I below. Pre-intervention relative fractional wall thickening, expressed as ischemic zone to non-ischemic zone (IZ/NIZ) ratio $\times 100$, at rest and during pacing, was similar between groups ($P=0.86$ and 0.96 , respectively). At 4 weeks following the intra-myocardial injection of ABM, improved regional wall thickening occurred at rest and during pacing, which was due to an ~50% increase in wall thickening of the collateral-dependent ischemic lateral wall. No significant changes were observed in the control animals, although a trend towards improvement in wall thickening was noted in the ischemic area during pacing at follow-up.

Table I. Regional Contractility of the Ischemic Wall

	Baseline	Follow-up	P
Rest			
ABM (%)	60 ± 32	83 ± 21	0.04
Control (%)	64 ± 46	69 ± 48	0.74
Pacing			
ABM (%)	36 ± 43	91 ± 44	0.056
Control (%)	37 ± 56	65 ± 56	0.23

ABM indicates autologous bone marrow.

Myocardial Perfusion Data

Regional myocardial perfusion assessment is shown in Table II below. There were no differences between the treated and control groups in the pre-intervention relative transmural myocardial perfusion, IZ/NIZ, at rest and during adenosine infusion ($P=0.42$ and

0.96, respectively). At 4 weeks following ABM injection, relative regional transmural myocardial perfusion at rest and during pacing improved significantly. This was due to an absolute improvement in myocardial perfusion in the ischemic zone both at rest (an increase of 57 %, $P=0.08$) and during adenosine infusion (37 %, $P=0.09$), while no significant changes were noted in absolute flow to the non-ischemic zone either at rest (increase of 35%, $P=0.18$) or during adenosine infusion (increase of 25 %, $P=0.26$). The increase in regional myocardial blood flow found in the ischemic zones consisted of both endocardial (73%) and epicardial (62%) regional improvement at rest, with somewhat lesser improvement during adenosine infusion (40% in both zones). At 4 weeks, the control group showed no differences in transmural, endocardial or epicardial perfusion in the ischemic and non-ischemic zones compared to pre-intervention values.

Table II. Regional Myocardial Perfusion

	Baseline	Follow-up	P
Rest			
ABM (%)	83 ± 12	98 ± 14	0.001
Control (%)	89 ± 9	92 ± 0.1	0.43
Adenosine			
ABM (%)	78 ± 12	89 ± 18	0.025
Control (%)	77 ± 5	78 ± 11	0.75

ABM indicates autologous bone marrow.

Histopathology and Vascularity Assessment

Assessment of BM smears before and after passing the filtrated aspirate through the injecting catheter revealed normal structure, absence of macro-aggregates and no evidence of cell fragments or distorted cell shapes. Histopathology at day 1 following injections
5 revealed acute lesions characterized by fibrin and inflammatory tract with dispersed cellular infiltration. The infiltrate was characterized by mononuclear cells that morphologically could not be differentiated from a BM infiltrate. Cellularity was maximal at 3 and 7 days and declined subsequently over time. At 3 weeks, more fibrosis was seen in the 0.5 ml injection-sites compared to the 0.2 ml. CD-34 immunostaining, designed to identify BM-
10 derived progenitor cells, was performed in sections demonstrating the maximal cellular infiltrate. Overall, it was estimated that 4-6% of the cellular infiltrate showed positive immunoreactivity to CD-34.

The ischemic territory in both groups was characterized by small areas of patchy necrosis occupying overall <10% of the examined ischemic myocardium. The non-ischemic
15 area revealed normal myocardial structure. Changes in the histomorphometric characteristics of the two groups were compared. There were no differences in the total area occupied by any blood vessel as well as the number of blood vessels > 50 μ m in diameter. However, comparison of the total areas stained positive for factor VIII (endothelial cells with and without lumen) in the ischemic versus the non-ischemic territories revealed
20 differences between the 2 groups. In the ABM group, the total endothelial cell area in the ischemic collateral-dependent zone was 100% higher than that observed in the non-ischemic territory (11.6 ± 5.0 vs. 5.7 ± 2.3 % area, $P=0.016$), whereas there was no significant difference in the control group (12.3 ± 5.5 vs. 8.2 ± 3.1 % area, $P=0.11$). However, other parameters of vascularity, including % area occupied by any blood vessel
25 and number of blood vessels > 50 μ m were similar in the ischemic and non-ischemic territories in both groups.

EXAMPLE 5

The effect of autologous bone marrow stimulated in vivo by pre-administration of GM-CSF in animal model of myocardial ischemia

Chronic myocardial ischemia was created in 16 pigs by the implantation of ameroid
5 constrictors around the left circumflex coronary artery. At four weeks minus 3 days after
ameroid implantation, 8 animals underwent subcutaneous injection of GM-CSF for 3
consecutive days (dose 10 $\mu\text{g/kg}$ per day) followed (on the fourth day and exactly 4 weeks
after ameroid implantation) by transendocardial injections of freshly aspirated ABM into
the ischemic zone using a transendocardial injection catheter (2.4 ml per animal injected at
10 12 sites) and 8 control animals without GM-CSF stimulation were injected with heparinized
saline. At baseline and 4 weeks later, animals underwent rest and pacing echocardiogram to
assess regional contractility (% myocardial thickening), and microsphere study to assess
collateral-dependent perfusion at rest and during adenosine infusion. Four weeks after
injection of ABM collateral flow (expressed as the ratio of ischemic/normal zone $\times 100$)
15 improved in ABM-treated pigs but not in controls (ABM: 85 ± 11 vs 72 ± 16 at rest,
 $P=0.026$; 83 ± 18 vs 64 ± 19 during adenosine, $P=0.06$; Controls: 93 ± 10 vs 89 ± 9 at rest,
 $P=0.31$; 73 ± 17 vs 75 ± 8 during adenosine, $P=0.74$). Similarly, contractility increased in
ABM-treated pigs but not in controls (ABM: 93 ± 33 vs 63 ± 27 at rest, $P=0.009$; 84 ± 36
vs 51 ± 20 during pacing, $P=0.014$, Controls: 72 ± 45 vs 66 ± 43 at rest, $P=0.65$; 70 ± 36 vs
20 43 ± 55 during pacing, $P=0.18$).

The results indicate that catheter-based transendocardial injection of ABM pre-
stimulated in vivo by GM-CSF administered systemically for 3 days, can augment
collateral perfusion and myocardial function in ischemic myocardium, findings suggesting
that this approach may constitute a novel therapeutic strategy for achieving optimal
25 therapeutic angiogenesis.

EXAMPLE 6

Treatment of a Human Patient

Bone marrow (~5 ml) will be aspirated from the iliac crest at approximately 60 minutes prior to initiation of the cardiac procedure using preservative-free heparinized glass
5 syringes (20 unit heparin/1 ml fresh BM). The aspirated bone marrow will be immediately macro-filtered using 300 μ and 200 μ stainless steel filters, sequentially. An experienced hematologist will perform the procedure under sterile conditions. The bone marrow smear will be evaluated to confirm a normal histomorphology of the bone marrow preparation.

Any of several procedures for delivery of an agent to the myocardium can be used.
10 These include direct transepical delivery, as could be achieved by a surgical approach (for example, but not limited to, a transthoracic incision or transthoracic insertion of a needle or other delivery device, or via thoracoscopy), or by any of several percutaneous procedures. Following is one example of percutaneous delivery. It should be emphasized that the following example is not meant to limit the options of delivery to the specific
15 catheter-based platform system described in the example--any catheter-based platform system can be used.

Using standard procedures for percutaneous coronary angioplasty, an introducer sheath of at least 8F is inserted in the right or left femoral artery. Following insertion of the arterial sheath, heparin is administered and supplemented as needed to maintain an ACT for
20 200-250 seconds throughout the LV mapping and ABM transplantation portion of the procedure. ACT will be checked during the procedure at intervals of no longer than 30 minutes, as well as at the end of the procedure to verify conformity with this requirement.

Left ventriculography is performed in standard RAO and/or LAO views to assist with guidance of NOGA-STAR™ and injection catheters, and an LV electro-mechanical
25 map is obtained using the NOGA-STAR™ catheter. The 8F INJECTION-STAR catheter is

placed in a retrograde fashion via the femoral sheath to the aortic valve. After full tip deflection, the rounded distal tip is gently prolapsed across the aortic valve and straightened appropriately once within the LV cavity.

The catheter (incorporating an electromagnetic tip sensor) is oriented to one of the
5 treatment zones (e.g. anterior, lateral, inferior-posterior or other). Utilizing the safety features of the NOGA™ system, needle insertion and injection is allowed only when stability signals will demonstrate an LS value of <3 . A single injection of 0.2 cc of freshly aspirated ABM will be delivered via trans-endocardial approach to the confines of up to two treatment zones with no closer than 5 mm between each injection site. The density of
10 injection sites will depend upon the individual subject's LV endomyocardial anatomy and the ability to achieve a stable position on the endocardial surface without catheter displacement or premature ventricular contractions (PVCs).

That freshly aspirated autologous bone marrow transplanted into ischemic myocardium is associated with improved collateral flow without adverse effects may be of
15 clinical importance for several reasons. The methodology reflected above took advantage of the natural capability of the bone marrow to induce a localized angiogenic response in an effective and apparently safe manner. Such an angiogenic strategy would probably be less costly than many others currently being tested. It would also avoid potential toxicity-related issues that are remote but definite possibilities with various gene-based approaches
20 using viral vectors.

The invention is based on the concept that autologous bone marrow may be an optimal source for cellular (an example would be endothelial progenitor cells, but the invention is not limited to such cells as many other cells in the bone marrow may contribute importantly to the angiogenic effect) and secreted, e.g., angiogenic growth factors, elements
25 necessary to promote new blood vessel growth and restore function when transferred to another tissue, such as ischemic heart or peripheral limbs. A patient's own bone marrow

can be used as the key therapeutic source to induce therapeutic angiogenesis and/or myogenesis in ischemic tissues, e.g., heart muscle and/or ischemic limb, with compromised blood perfusion due to arterial obstructions. The patient's own bone marrow is aspirated, i.e., autologous bone marrow donation, processed, and injected directly into ischemia
5 and/or adjacent non-ischemic tissue, e.g., heart muscle and/or ischemic limb, to promote blood vessel growth.

The autologous bone marrow and/or bone marrow products are injected into the heart muscle, e.g., the myocardium, by use of either a catheter-based trans-endocardial injection approach or a surgical (open chest or via thoracoscopy) trans-epicardial
10 thoracotomy approach. Those two delivery strategies can be used to achieve the same therapeutic goal by promoting the incorporation and integration of angiogenic bone marrow elements in the target organ tissue, e.g., heart muscle and/or ischemic limb.

According to the invention, effective amounts of autologous bone marrow are administered for treatment. As would be appreciated by experienced practitioners, the
15 amount administered will depend upon many factors, including, but not limited to, the intended treatment, the severity of a condition being treated, the size and extent of an area to be treated, etc. With regard to treatment according to the invention, a representative protocol would be to administer quantities of from about 0.2 to about 0.5 ml of autologous bone marrow in each of from about 12 to about 25 injections, for a total of from about 2.4
20 to about 6 ml of autologous bone marrow being administered. Each dose administered could preferably comprise from about 1 to about 2 percent by volume of heparin or another blood anticoagulant, such as coumadin. When the autologous bone marrow has been cultured or stimulated and/or is being administered in combination with other pharmaceuticals or the like, the quantity of autologous bone marrow present should be
25 approximately the same in each dose and/or the total of the autologous bone marrow administered should be about the same as described above. It is believed that the total

number of cells of autologous bone marrow administered in each treatment should be on the order of from about 10^7 to 5×10^8 .

Optimization of angiogenic gene expression requires the co-administration of various angiogenic stimulants with the autologous bone marrow. Thus, according to the invention autologous bone marrow transplantation is injected either as a "stand alone" therapeutic agent or combined with any pharmacologic drug, protein or gene or any other compound or intervention that may enhance bone marrow production of angiogenic growth factors and/or promote endothelial cell proliferation, migration, and blood vessel tube formation. The "combined" agent(s) can be administered directly into the patient or target tissue, or incubated ex-vivo with bone marrow prior to injection of bone marrow into the patient. Examples of these "combined" agents (although not limited to these agents) are Granulocyte-Monocyte Colony Stimulatory Factor (GM-CSF), Monocyte Chemoattractant Protein 1 (MCP 1), EPAS1, or Hypoxia Inducible Factor-1 (HIF-1). The stimulation of the bone marrow could be by the direct exposure of the bone marrow to the factors in the form of proteins, or the bone marrow cells can be transfected with vectors carrying the relevant genes. For example, bone marrow can be transfected with a plasmid vector, or with an adenoviral vector, carrying the HIF-1 or EPAS1 transgenes. An example of an intervention that may enhance bone production of angiogenic factors is ex-vivo exposure of bone marrow cells to hypoxia. This intervention can be used alone with bone marrow, or in combination with any of the factors outlined above. These optimization strategies are designed to increase the production of vascular endothelial growth factor (VEGF) expression and/or other cytokines with angiogenic activity prior to the direct injection of the bone marrow into the heart or any peripheral ischemic tissue. In a broad sense, the invention comprises intramyocardial injection of autologous bone marrow with any agent that would become available to cause stimulation of bone marrow and/or ex-vivo or in vivo

stimulation of any angiogenic growth factor production by the bone marrow or its stromal microenvironment.

Delivery to patients will vary, dependent upon the clinical situation. For example, patients with refractory coronary artery disease or ischemic peripheral vasculopathy who will be candidates for a bone marrow aspiration procedure followed by autologous bone marrow myocardial or limb transplantation directed into the ischemic tissue or its borderline zone and/or normal tissue that may serve as the source for collateral or cellular supply to the diseased tissue for the purposes of therapeutic angiogenesis and/or myogenesis. For example, patients with refractory coronary artery disease or ischemic peripheral vasculopathy who will be candidates for a bone marrow aspiration procedure followed by autologous bone marrow myocardial or limb transplantation directed into the ischemic tissue or its borderline zone and/or normal tissue that may serve as the source for collateral or cellular supply to the diseased tissue for the purposes of therapeutic angiogenesis and/or myogenesis. This procedure will involve the use of a bone marrow aspiration procedure, bone marrow harvesting and processing, followed by the use of the autologous bone marrow or its elements (growth factors and/or cellular elements being isolated from the patient's own bone marrow), with or without any ex-vivo stimulation of its delivery forms, to be injected into the ischemic or non ischemic myocardium and/or peripheral ischemic tissue (such as limb ischemia). The bone marrow will be kept in standard anti-coagulation/anti-aggregation solution (containing sodium citrate and EDTA) and kept in 4° C in sterile medium until the time of its use.

Upon its use, the bone marrow will be filtered to avoid injecting remaining blood clots or macroaggregates into the target tissue.

The bone marrow, with or without a stimulatory agent in any of its delivery forms, or with or without having been transfected with a vector carrying a transgene that is designed to enhance the angiogenesis effect of the bone marrow, will be injected into the

heart muscle, i.e., in therapeutic myocardial angiogenesis or therapeutic myogenesis, using either any catheter-based trans-endocardial injection device or via a surgical (open chest) trans-epicardial thoracotomy approach, or any other approach that allows for transepicardial delivery. In the case of treatment of limb ischemia the bone marrow will be transferred by
5 a direct injection of the bone marrow or its elements, with or without ex-vivo or in vivo stimulation in any of its delivery forms, into the muscles of the leg.

The volume of injection per treatment site will probably range between 0.1-5.0 cc per injection site, dependent upon the specific bone marrow product and severity of the ischemic condition and the site of injection. The total number of injections will probably
10 range between 1-50 injection sites per treatment session.

The preceding specific embodiments are illustrative of the practice of the invention. It is to be understood, however, that other expedients known to those skilled in the art or disclosed herein, may be employed without departing from the spirit of the invention or the scope of the appended claims.

We claim:

1. A method of enhancing collateral blood vessel formation which comprises the step of directly administering to a desired site an effective amount of autologous bone marrow.
- 5 2. The method of Claim 1, wherein the autologous bone marrow is injected.
3. The method of Claim 1, wherein the autologous bone marrow is injected intramyocardially.
4. The method of Claim 3, wherein the autologous bone marrow is injected trans-epicardially or trans-endocardially.
- 10 5. The method of Claim 4, wherein with the trans-endocardial approach a catheter-based approach is used.
6. The method of Claim 1, wherein the autologous bone marrow is injected peripherally into the limb intramuscularly.
7. The method of Claim 1, wherein the autologous bone marrow has been
15 stimulated.
8. The method of Claim 7, wherein the autologous bone marrow has been stimulated by contact with one or more cytokines or other proteins or stimulating agents.
9. The method of Claim 7, wherein the cytokines are selected from the group consisting of HIF-1, EPAS1, MCP-1, and CM-CSF.
- 20 10. The method of Claim 7, wherein the autologous bone marrow has been transfected with vectors carrying relevant genes.

11. The method of Claim 10, wherein the autologous bone marrow has been transfected with a plasmid vector or an adenoviral vector, or any other vector demonstrated to be effective for gene transfer, carrying the HIF-1 or EPAS1 transgene, or any other transgene demonstrated to be effective in enhancing the capacity of bone marrow to induce angiogenesis.
12. The method of Claim 7, wherein the autologous bone marrow has been stimulated by transient exposure to hypoxia or a form of energy.
13. The method of Claim 7, wherein conditioned medium derived from autologous bone marrow growing in culture is injected into the ischemic heart or limb.
14. The method of Claim 1, wherein the autologous bone marrow is administered in combination with a pharmacological drug, protein, or gene or any other compound or therapy that may enhance bone marrow production of angiogenic growth factors and/or promote endothelial cell proliferation, migration, or blood vessel formation.
15. The method of Claim 14, wherein the autologous bone marrow and the other agent or agents are administered together.
16. The method of Claim 14, wherein the autologous bone marrow and the other agent or agents are combined prior to administration.
17. The method of Claim 16, wherein the autologous bone marrow has been stimulated.
18. The method of Claim 1, wherein ischemic tissue is treated.
19. A method of promoting the development of newly implanted myocardial cells which comprises the step of directly administering an effective amount of autologous bone marrow.

20. The method of Claim 19, wherein the autologous bone marrow is injected.
21. The method of Claim 19, wherein the autologous bone marrow is injected intramyocardially.
22. The method of Claim 21, wherein the autologous bone marrow is injected
5 trans-epicardially or trans-endocardially.
23. The method of Claim 22, wherein with the trans-endocardial approach a catheter-based approach is used.
24. The method of Claim 19, wherein the autologous bone marrow is injected peripherally into the limb intramuscularly.
- 10 25. The method of Claim 19, wherein the autologous bone marrow has been stimulated.
26. The method of Claim 25, wherein the autologous bone marrow has been stimulated by contact with one or more cytokines or other proteins or stimulating agents.
27. The method of Claim 25, wherein the cytokines are selected from the group
15 consisting of HIF-1, EPAS1, MCP-1, and CM-CSF.
28. The method of Claim 25, wherein the autologous bone marrow has been transfected with vectors carrying relevant genes.
29. The method of Claim 28, wherein the autologous bone marrow has been transfected with a plasmid vector or an adenoviral vector, or any other vector demonstrated
20 to be effective for gene transfer, carrying the HIF-1 or EPAS1 transgene, or any other transgene demonstrated to be effective in enhancing the capacity of bone marrow to induce angiogenesis.

30. The method of Claim 25, wherein the autologous bone marrow has been stimulated by transient exposure to hypoxia or a form of energy.

31. The method of Claim 25, wherein conditioned medium derived from autologous bone marrow growing in culture is injected into the ischemic heart or limb.

5 32. The method of Claim 19, wherein the autologous bone marrow is administered in combination with a pharmacological drug, protein, or gene or any other compound or therapy that may enhance bone marrow production of angiogenic growth factors and/or promote endothelial cell proliferation, migration, or blood vessel formation.

10 33. The method of Claim 32, wherein the autologous bone marrow and the other agent or agents are administered together.

34. The method of Claim 32, wherein the autologous bone marrow and the other agent or agents are combined prior to administration.

35. The method of Claim 34, wherein the autologous bone marrow has been stimulated.

15 36. A method of improving the electrical conductivity of the heart of a patient with cardiac electrical pathway impairment, which comprises the step of administering an effective amount of autologous bone marrow.

37. The method of Claim 36, wherein the autologous bone marrow is injected.

20 38. The method of Claim 36, wherein the autologous bone marrow is injected intramyocardially.

39. The method of Claim 38, wherein the autologous bone marrow is injected trans-epicardially or trans-endocardially.

40. The method of Claim 39, wherein with the trans-endocardial approach a catheter-based approach is used.

41. The method of Claim 36, wherein with the trans-endocardial approach the autologous bone marrow is injected peripherally into the limb intramuscularly.

5 42. The method of Claim 36, wherein the autologous bone marrow has been stimulated.

43. The method of Claim 42, wherein the autologous bone marrow has been stimulated by contact with one or more cytokines or other proteins or stimulating agents.

44. The method of Claim 42, wherein the cytokines are selected from the group
10 consisting of HIF-1, EPAS1, MCP-1, and CM-CSF.

45. The method of Claim 42, wherein the autologous bone marrow has been transfected with vectors carrying relevant genes.

46. The method of Claim 45, wherein the autologous bone marrow has been transfected with a plasmid vector or an adenoviral vector, or any other vector demonstrated
15 to be effective for gene transfer, carrying the HIF-1 or EPAS1 transgene, or any other transgene demonstrated to be effective in enhancing the capacity of bone marrow to induce angiogenesis.

47. The method of Claim 42, wherein the autologous bone marrow has been stimulated by transient exposure to hypoxia or a form of energy.

20 48. The method of Claim 42, wherein conditioned medium derived from autologous bone marrow growing in culture is injected into the ischemic heart or limb.

49. The method of Claim 36, wherein the autologous bone marrow is administered in combination with a pharmacological drug, protein, or gene or any other

compound or therapy that may enhance bone marrow production of angiogenic growth factors and/or promote endothelial cell proliferation, migration, or blood vessel formation.

50. The method of Claim 49, wherein the autologous bone marrow and the other agent or agents are administered together.

5 51. The method of Claim 49, wherein the autologous bone marrow and the other agent or agents are combined prior to administration.

52. The method of Claim 51, wherein the autologous bone marrow has been stimulated.

53. A method of enhancing myocardial function in a patient with impaired
10 myocardial function, which comprises the step of administering an effective amount of autologous bone marrow.

54. The method of Claim 53, wherein the autologous bone marrow is injected.

55. The method of Claim 53, wherein the autologous bone marrow is injected intramyocardially.

15 56. The method of Claim 55, wherein the autologous bone marrow is injected trans-epicardially or trans-endocardially.

57. The method of Claim 56, wherein with the trans-endocardial approach a catheter-based approach is used.

58. The method of Claim 53, wherein the autologous bone marrow is injected
20 peripherally into the limb intramuscularly.

59. The method of Claim 53, wherein the autologous bone marrow has been stimulated.

60. The method of Claim 59, wherein the autologous bone marrow has been stimulated by contact with one or more cytokines or other proteins or stimulating agents.

61. The method of Claim 59, wherein the cytokines are selected from the group consisting of HIF-1, EPAS1, MCP-1, and CM-CSF.

5 62. The method of Claim 59, wherein the autologous bone marrow has been transfected with vectors carrying relevant genes.

63. The method of Claim 62, wherein the autologous bone marrow has been transfected with a plasmid vector or an adenoviral vector, or any other vector demonstrated to be effective for gene transfer, carrying the HIF-1 or EPAS1 transgene, or any other
10 transgene demonstrated to be effective in enhancing the capacity of bone marrow to induce angiogenesis.

64. The method of Claim 59, wherein the autologous bone marrow has been stimulated by transient exposure to hypoxia or a form of energy.

65. The method of Claim 59, wherein conditioned medium derived from
15 autologous bone marrow growing in culture is injected into the ischemic heart or limb.

66. The method of Claim 53, wherein the autologous bone marrow is administered in combination with a pharmacological drug, protein, or gene or any other compound or therapy that may enhance bone marrow production of angiogenic growth factors and/or promote endothelial cell proliferation, migration, or blood vessel formation.

20 67. The method of Claim 66, wherein the autologous bone marrow and the other agent or agents are administered together.

68. The method of Claim 66, wherein the autologous bone marrow and the other agent or agents are combined prior to administration.

69. The method of Claim 68, wherein the autologous bone marrow has been stimulated.

70. A method of treating an atrial or ventricular condition in the heart of a patient, which comprises the step of administering an effective amount of autologous bone marrow.

71. The method of Claim 70, wherein the autologous bone marrow is injected.

72. The method of Claim 70, wherein the autologous bone marrow is injected intramyocardially.

73. The method of Claim 72, wherein the autologous bone marrow is injected trans-epicardially or trans-endocardially.

74. The method of Claim 73, wherein with the trans-endocardial approach a catheter-based approach is used.

75. The method of Claim 70, wherein the autologous bone marrow is injected peripherally into the limb intramuscularly.

76. The method of Claim 70, wherein the autologous bone marrow has been stimulated.

77. The method of Claim 76, wherein the autologous bone marrow has been stimulated by contact with one or more cytokines or other proteins or stimulating agents.

78. The method of Claim 76, wherein the cytokines are selected from the group consisting of HIF-1, EPAS1, MCP-1, and CM-CSF.

79. The method of Claim 76, wherein the autologous bone marrow has been transfected with vectors carrying relevant genes.

80. The method of Claim 79, wherein the autologous bone marrow has been transfected with a plasmid vector or an adenoviral vector, or any other vector demonstrated to be effective for gene transfer, carrying the HIF-1 or EPAS1 transgene, or any other transgene demonstrated to be effective in enhancing the capacity of bone marrow to induce
5 angiogenesis.

81. The method of Claim 76, wherein the autologous bone marrow has been stimulated by transient exposure to hypoxia or a form of energy.

82. The method of Claim 76, wherein conditioned medium derived from autologous bone marrow growing in culture is injected into the ischemic heart or limb.

10 83. The method of Claim 70, wherein the autologous bone marrow is administered in combination with a pharmacological drug, protein, or gene or any other compound or therapy that may enhance bone marrow production of angiogenic growth factors and/or promote endothelial cell proliferation or migration, or blood vessel formation.

15 84. The method of Claim 83, wherein the autologous bone marrow and the other agent or agents are administered together.

85. The method of Claim 83, wherein the autologous bone marrow and the other agent or agents are combined prior to administration.

20 86. The method of Claim 85, wherein the autologous bone marrow has been stimulated.

87. A composition for the treatment of a cardiac or myocardial condition, which comprises an effective amount of autologous bone marrow, wherein the cardiac or myocardial condition is treated.

88. The composition of Claim 87, wherein the autologous bone marrow has been stimulated.

89. The composition of Claim 88, wherein the autologous bone marrow has been stimulated by contact with one or more cytokines or other proteins or stimulating agents.

5 90. The composition of Claim 89, wherein the cytokines are selected from the group consisting of HIF-1, EPAS1, MCP-1, and CM-CSF.

91. The composition of Claim 88, wherein the autologous bone marrow has been transfected with vectors carrying relevant genes.

92. The composition of Claim 91, wherein the autologous bone marrow has been
10 transfected with a plasmid vector or an adenoviral vector, or any other vector demonstrated to be effective for gene transfer, carrying the HIF-1 or EPAS1 transgene, or any other transgene demonstrated to be effective in enhancing the capacity of bone marrow to induce angiogenesis.

93. The composition of Claim 89, wherein the autologous bone marrow has been
15 stimulated by exposure to hypoxia.

94. The composition of Claim 89, wherein conditioned medium derived from autologous bone marrow growing in culture is injected into the ischemic heart or limb.

95. The composition of Claim 87, wherein the autologous bone marrow is administered in combination with a pharmacological drug, protein, or gene or any other
20 compound or therapy that may enhance bone marrow production of angiogenic growth factors and/or promote endothelial cell proliferation, migration, or blood vessel formation.

96. The composition of Claim 87 which comprises heparin or another anticoagulant.

97. The composition of Claim 87 for enhancing collateral blood vessel formation.
98. The composition of Claim 87 for promoting the development of newly implanted myocardial cells.
- 5 99. The composition of Claim 87 for improving the electrical conductivity of the heart of a patient with cardiac electrical pathway impairment.
100. The composition of Claim 87 for enhancing the myocardial function in a patient with impaired myocardial function.
101. The composition of Claim 87 for treating a left or right ventricular condition
10 causing impaired heart function in the heart of a patient.
102. The composition of Claim 87 for affecting the contractility of a patient's heart.

1 / 2




Fig. 1




Fig. 2

2 / 2




Fig. 3




Fig. 4

INTERNATIONAL SEARCH REPORT

International application No.

PCT/US00/08353

A. CLASSIFICATION OF SUBJECT MATTER IPC(7) : A61K48/00. US CL : 424/93.7. According to International Patent Classification (IPC) or to both national classification and IPC		
B. FIELDS SEARCHED Minimum documentation searched (classification system followed by classification symbols) U.S. : 424/93.1, 424/93.7. Documentation searched other than minimum documentation to the extent that such documents are included in the fields searched Electronic data base consulted during the international search (name of data base and, where practicable, search terms used) Medline, Embase, Scisearch, WEST, CAPLUS.		
C. DOCUMENTS CONSIDERED TO BE RELEVANT		
Category *	Citation of document, with indication, where appropriate, of the relevant passages	Relevant to claim No.
A,P	BRUGGER, et al. Ex Vivo Manipulation of Hematopoietic Stem and Progenitor Cells. Seminars in Hematology, 2000, Vol. 37, No. 1, pages 42-49.	1-102
Y	FIELDING, et al. Autologous Bone Marrow Transplantation. Current Opinion in Hematology, 1994, Vol. 1, pages 412-417. See page 1.	1-102
Y	VAUGHAN, et al. Incorporating Bone Marrow Transplantation Into NCCN Guidelines. Oncology, 1998, Vol. 12, No. 11A, pages 390-392. See page 391.	1-102
Y	SIMNETT, et al. Autologous Stem Cell Transplantation for Malignancy: A Systematic Review of the Literature. Clin Lab Haem, 2000, Vol. 22, pages 61-72.	1-102
Y,P	BLUME, et al. A Review of Autologous Hematopoietic Cell Transplantation. Biology of Blood and Marrow Transplantation, 2000, Vol. 6, pages 1-12.	1-102
X,P	NOISHIKI, et al. Angiogenic Growth Factor Release System for In vivo Tissue Engineering: A Trial of Bone Marrow Transplantation into Ischemic Myocardium. J Artif Organs, 1999, Vol. 2, pages 85-91.	1-102
X	KANJ, et al. Myocardial Ischemia Associated With High-dose Carmustine Infusion. Cancer, 1991, Vol. 68, No. 9, pages 1910-1912.	1-102
<input checked="" type="checkbox"/> Further documents are listed in the continuation of Box C. <input type="checkbox"/> See patent family annex.		
* Special categories of cited documents:		
"A"	document defining the general state of the art which is not considered to be of particular relevance	"T" later document published after the international filing date or priority date and not in conflict with the application but cited to understand the principle or theory underlying the invention
"B"	earlier application or patent published on or after the international filing date	"X" document of particular relevance; the claimed invention cannot be considered novel or cannot be considered to involve an inventive step when the document is taken alone
"C"	document which may throw doubts on priority claim(s) or which is cited to establish the publication date of another citation or other special reason (as specified)	"Y" document of particular relevance; the claimed invention cannot be considered to involve an inventive step when the document is combined with one or more other such documents, such combination being obvious to a person skilled in the art
"O"	document referring to an oral disclosure, use, exhibition or other means	"Z" document member of the same patent family
"P"	document published prior to the international filing date but later than the priority date claimed	
Date of the actual completion of the international search 8 June 2000		Date of mailing of the international search report 12 JUL 2000
Name and mailing address of the ISA/US Commissioner of Patents and Trademarks Box PCT Washington, D.C. 20231 Facsimile No. (703)305-3230		Authorized officer David Nikodem Telephone No. (703) 408-1123